Gujarat Kidney and Super Speciality Investor Presentation: Key Takeaways
Q2 FY27 revenue ₹3,809L (+195% YoY), PAT ₹660L (17.3% margin). H1 FY27 revenue ₹7,238L, PAT ₹1,192L. Growth is acquisition-led, with Dubai entry.
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
7 announcements with these filters
Q2 FY27 revenue ₹3,809L (+195% YoY), PAT ₹660L (17.3% margin). H1 FY27 revenue ₹7,238L, PAT ₹1,192L. Growth is acquisition-led, with Dubai entry.
Gujarat Kidney filed Brickwork's monitoring agency report for the quarter ended September 30, 2026. It confirms no deviation from the IPO fund-utilisation objects.
Gujarat Kidney and Super Speciality Ltd reported revenue from operations of ₹38.1 Cr (+195.3% YoY) and net profit of ₹6.6 Cr (+127.6% YoY) for Q2 FY27.
Gujarat Kidney will hold a board meeting on 04 Nov 2026 to consider unaudited quarterly results. The trading window closes from 01 Oct 2026.
This is a routine quarterly shareholding pattern disclosure for the period ended September 30, 2026, filed under SEBI Regulation 31.
Gujarat Kidney and Super Speciality Limited held its 7th Annual General Meeting on September 28, 2026. Shareholders approved financial statements, director appointments, and various regulatory borrowing and investment limits.
Gujarat Kidney and Super Speciality Limited issued a corrigendum to its FY 2025-26 Annual Report. The update includes missing Secretarial Audit observations and management responses.